Application of the Tumor Site Recognizable and Dual-Responsive Nanoparticles for Combinational Treatment of the Drug-Resistant Colorectal Cancer
- 25 March 2020
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 37 (4) , 1-14
Abstract
Purpose Combination of PCI and chemotherapy represents a promising strategy for combating drug resistance of cancer. However, poor solubility of photosensitizers and unselectively released drugs at unwanted sites significantly impaired the treatment efficacy. Therefore, in the present study, we aimed to develop a nano-platform which could efficiently co-entrapping photosensitizers and chemotherapeutics for active targeting therapy of drug resistant cancers. Methods Two pro-drugs were respectively developed by covalently linking the Ce6 with each other via the GSH-sensitive linkage and the PTX with mPEG-PLA-COOH through the ROS sensitive-linker. The dual-responsive nanoparticles (PNP-Ce6) was developed by emulsion/solvent evaporation method and further modified with tLyp-1 peptides. Physicochemical properties of nanoparticles were determined by the TEM and DLC. Cellular uptake assay was investigated with the Ce6 acting as the fluorescent probe and cell growth was studied by the MTT experiment. In vivo tumor targeting and anti-tumor assay was investigated on the colorectal cancer-bearing mice. Results The developed tPNP-Ce6 were stable enough under the normal physiological conditions. However, free Ce6 and PTX were completely released when exposed the tPNP-Ce6 to the redox environment. Excellent tumor-targeting drug delivery was achieved by the tPNP-Ce6, which in turn resulted in satisfactory anit-tumor effect. Of great importance, super inhibition effect on tumor progress was achieved by the combination therapy when compared with the group only received with chemotherapy.. Conclusion The results obtained in the present study indicated that the developed tPNP-Ce6 may have great potential in enhancing the therapeutic efficacy of drug-resistant colorectal cancer. Left: Targeting delivery of drug to tumor site by the tumor recognizable and dual-responsive nanoparticles and penetrating into tumor inner via the mediation of irradiation. Right: Nanoparticle distribution within tumor tissues with green represents the blood vessels stained with CD31, blue signal represents the cell nuclei stained with DAPI and red shows fluorescence of Ce6 as the indicator of the nanoparticles.Keywords
This publication has 36 references indexed in Scilit:
- Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancerBiomaterials, 2013
- Treatment of oral lichen planus with methylene blue mediated photodynamic therapy – a clinical studyPhotodermatology, Photoimmunology & Photomedicine, 2012
- A review of NIR dyes in cancer targeting and imagingBiomaterials, 2011
- Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomesInternational Journal of Pharmaceutics, 2011
- High‐Contrast Fluorescence Imaging of Tumors In Vivo Using Nanoparticles of Amphiphilic Brush‐Like Copolymers Produced by ROMPAngewandte Chemie International Edition, 2011
- Indocyanine Green-Containing Nanostructure as Near Infrared Dual-Functional Targeting Probes for Optical Imaging and Photothermal TherapyMolecular Pharmaceutics, 2011
- Tissue-Penetrating Delivery of Compounds and Nanoparticles into TumorsCancer Cell, 2009
- Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug BindingScience, 2009
- Biodegradable pH-Sensing Dendritic Nanoprobes for Near-Infrared Fluorescence Lifetime and Intensity ImagingJournal of the American Chemical Society, 2007
- Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude miceJournal of Cancer Research and Clinical Oncology, 2007